Clinical Trial Update: In Vivo PARP-1 Expression With 18F-FTT PET/CT in Pancreatic Cancer [EARLY_Phase 1]

View source ↗

Summary

A Phase 1 imaging trial evaluating in vivo PARP-1 expression with the PET tracer 18F-FTT in pancreatic cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• 18F-FTT

Snippet

Sponsor: Abramson Cancer Center at Penn Medicine | Conditions: Pancreatic Cancer | EARLY_Phase 1 | Status: TERMINATED